Why the study?
Does capillary blood sampling yield comparable doxorubicin plasma concentrations to venous blood sampling in patients receiving doxorubicin?
Does capillary blood sampling yield comparable doxorubicin plasma concentrations to venous blood sampling in patients receiving doxorubicin?
Capillary blood sampling provides comparable doxorubicin plasma concentrations to venous sampling, offering a less traumatic alternative for pharmacokinetic studies, particularly in pediatric patients.
May support less invasive doxorubicin monitoring; leaves open prospective validation before replacing venous sampling.
Doxorubicin, an anthraquinone glycoside, is currently one of the clinically most important antineoplastic drugs. The aim of the present study was to identify potential concentration differences of doxorubicin in plasma from capillary and venous blood samples. Sixteen patients (seven females and nine males; median age: 37 years, range: 1-77 years) were included. The quantitative analysis of doxorubicin was carried out by reversed-phase liquid chromatography with fluorometric detection. The concentration of doxorubicin in capillary and venous samples were closely correlated (r=0.98; p<0.0001). The median plasma concentration ratio capillary/venous was 1.13 (95% confidence interval: 1.06-1.20) and not affected either by plasma drug concentration, age or the body mass index of the patient. The concentration ratio was significantly higher in males (median: 1.18) than in females (median: 1.01). The observed concentration differences of doxorubicin in plasma from capillary and venous samples are of minor importance only. Capillary blood sampling is recommended for use in pharmacokinetic studies of doxorubicin, especially in pediatric patients, in order to avoid sometimes traumatic venous blood sampling.
No takes yet. Share an insight, caveat, or question.
Palm et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: